An interventional study of Mechanical circulatory support with the Pulsecath iVAC2L device in High-risk PCI and Coronary Artery Disease Risk High, sponsored by Amsterdam UMC, location VUmc. Recruiting at 8 sites in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-02.
Sponsored by Amsterdam UMC, location VUmc · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 283 studies in Coronary Artery Disease with a site in Netherlands — 44 open to participants now, 66 under way, 5 of them phase 3. Coronary Artery Disease · Netherlands.
Among the 283 studies in Coronary Artery Disease with a site in Netherlands, this one is the 156th largest by planned enrollment of the 198 interventional ones that give a count, is one of 8 that started in 2024, is one of 109 with no phase, reaches primary completion later than 38 of the 65 other live ones, and was the 278th registered.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →44 of the 283 studies in Coronary Artery Disease with a site in Netherlands are open now. Recruiting first, the newest first:
EBI Anti Sepsis BV · Sites in Netherlands, United States, Belgium and 1 more country
Ages 18+
Catharina Ziekenhuis Eindhoven · Sites in Netherlands, Belgium
Ages 18–85 · Healthy volunteers
University Medical Center Groningen · Sites in Netherlands
Ages 18+
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Sites in Netherlands
Ages 18+
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Sites in Netherlands
Ages 18+
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
283 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 25 · Phase 3 45 · Phase 4 21
First in 1998; this study’s year is marked. 8 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 98 is below the median of 123 across 3,011 interventional studies indexed under Coronary Artery Disease.
Median enrollment 348 across the 198 interventional studies, 598 across the 84 observational. Of the 172 that completed or were terminated, 49 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
129 of 283 have an industry lead sponsor. The 10 most frequent:
Amsterdam UMC, location VUmc is the lead sponsor of 305 studies on the registry; 84 are open to participants now.
Amsterdam UMC, location VUmc has 8 studies filed under Coronary Artery Disease — fewer than ten, so there is no comparison to draw.
9 of the studies in Coronary Artery Disease with a site in Netherlands that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07357675Phase 3EBI Anti Sepsis BVA Clinical Trial To Investigate The Effect Of EA-230 On Hospital Length Of Stay In Patients With Coronary Artery Disease (CAD) Undergoing Coronary Artery Bypass Grafting (CABG) Surgery. | 2027-10-01 |
| NCT06977295Instituto de Investigación Biomédica de SalamancaEvaluation of a Diagnostic Software for Coronary Artery Disease Using Retrospective CCTA Data (CODEX-1 Study) | 2026-11-30 |
| NCT05783804Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Plaque Reversal With Early, Aggressive Lipid Lowering Therapy | 2026-12 |
| NCT06995183E.S.stroesHeart CT Imaging to Detect Early Coronary Artery Disease in First-Degree Relatives With High or Low Lipoprotein(a) Identified Through Family Screening | 2026-12-31 |
| NCT07380217Amsterdam UMC, location VUmcUse of Mechanical Left ventricuLar Unloading in Complex Higher-risk Indicated Procedures | 2027-03-01 |
Add all 9 to your calendar (.ics) → With an account.
Among the 283 studies in Coronary Artery Disease with a site in Netherlands, from their registry updates:
This tab as a report to print or save as PDF → With an account.
If there is a narrowing or blockage in the coronary arteries of the heart, the cardiologist may choose to treat this blockage. This is called percutaneous coronary intervention (PCI), which involves both balloon angioplasty and the placement of a stent. PCI is a commonly performed and safe procedure. However, in your case, the procedure is more complicated than usual due to the location and nature of the narrowing, the required technique for the intervention, and the fact that your heart function is reduced. As a result, your PCI will carry a higher risk than usual.
During the procedure, balloons are inflated to clear the blockage, and a stent is placed to keep the artery open. This temporarily reduces or even stops the blood and oxygen supply to a large portion of the heart. This moment presents a higher risk for complications, such as low blood pressure or cardiac arrest. As a result, the heart may not pump blood effectively throughout the body, which can lead to oxygen deprivation in other organs.
To help the heart in this situation, it is possible to insert a mechanical heart pump during the procedure. This form of support is introduced via an artery in the groin into your left ventricle. The pump helps the heart function and may improve the circulation to the body's organs. On the other hand, the placement of the pump increases the chance of complications. Therefore, there are both potential benefits and risks. It is currently unclear whether PCI with the temporary pump can be performed more safely than without it.
This study aims to investigate whether mechanical circulatory support, specifically with the Pulsecath iVAC2L, leads to improved outcomes for patients undergoing high-risk PCI.
During the last three to four decades percutaneous coronary intervention (PCI) tools and techniques have improved immensely. Currently, PCI is the most widely used approach for myocardial revascularization. In general, elective PCI is considered a safe and relatively low-risk procedure.
However, patients with left main or complex coronary lesions or impaired left ventricular function remain at high risk for peri-procedural and post-procedural hemodynamic instability and death.
Mechanical circulatory support (MCS) devices, such as intra-aortic balloon pump (IABP) and Impella (Impella 2.5 and CP), have emerged as potential tools to avoid hemodynamic instability during these CHIP coronary interventions. These devices have shown to improve hemodynamics / cardiac output during complex PCI procedures, although the benefit of mechanical circulatory support in CHIP PCI remains debated and no clear benefit on patient outcomes has been shown. A recent large scale analysis favoured Impella as opposed to IABP. The use of these devices, especially Impella, is associated with increased risk for complications such as bleeding. The use of MCS for optimizing peri-procedural hemodynamic support needs to be balanced out against the potential risk for MCS related complications.
Recently the PulseCath iVAC 2L was introduced. This is a pulsatile pump, placed in the left ventricle, that ejects blood into the ascending aorta at a flow up to 2L/min. Theoretically, pulsatility maintains the physiological vascular responses and endothelial function at the level of the -systemic and -micro circulation and might offer benefit when compared to continues flow devices such as Impella. In contrast, IABP (which also offers pulsatile support), lacks the possibility of active unloading. Therefore, the combination of those features in the PulseCath iVAC2L is unique.
Recent studies performed with the PulseCath iVAC2L in the setting of CHIP PCI demonstrated hemodynamic advantages with afterload reduction, increased stroke volume and higher cardiac output. Also, the device was deemed safe in terms of complications. Samol et al. showed in a prospective cohort study that the use of IVAC2L was non-inferior to Impella in terms of feasibility and safety, even if complications occur. Other advantages of the IVAC2L are its relatively simple use and lower costs when compared to other mechanical circulatory support devices such as the Impella family. Considering that the IVAC2L is powered by an IABP console, the possibility of widespread use adds an even greater advantage.
So far, MCS facilitated CHIP has not been proven beneficial compared to a conservative (non-supported) high-risk procedure. Although high-risk criteria parameters such as coronary anatomy (location and complexity), co-morbid conditions, and concomitant cardiac disease (structural or valvular disease, left ventricular dysfunction) are well known, no intrinsic value of each of these components is determined. The recent PULSE trial shed some light on this gap of knowledge by showing possible additional hemodynamic benefit for patients with mitral regurgitation, who presented with an acute coronary syndrome (ACS) and who had higher cardiac filling pressures at baseline. Therefore, MCS-facilitated high-risk PCI might be beneficial if used in ACS patients or patients with (left-sided) congestion (stabilized acutely decompensated heart failure) with low hemodynamic tolerance. However, due to the low number of patients enrolled and non-randomized nature of this study, conclusions should be drawn with caution. To this day, no randomized controlled trials have been executed with the PulseCath iVAC2L in this subset of CHIP patients who are thought to benefit from an MCS-facilitated PCI. Its place in the setting of CHIP PCI remains to be elucidated.
Research hypothesis:
Prophylactic percutaneous mechanical left ventricular unloading by insertion of the PulseCath iVAC2L during complex coronary stenting (complex left main disease or equivalent or last remaining vessel) at risk for prolonged procedural ischemia in patients with severely reduced LV function is superior to a mechanical unassisted PCI procedure.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
for Pulsecath IVAC2L:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will undergo high-risk PCI without upfront use of MCS
Patients will undergo high-risk PCI with upfront use of the Pulsecath iVAC2L (MCS)
Device: Mechanical circulatory support with the Pulsecath iVAC2L device
The Pulsecath iVAC2L is a pulsatile pump, placed in the left ventricle, that ejects blood into the ascending aorta at a flow up to 2L/min. Theoretically, pulsatility maintains the physiological vascular responses and endothelial function at the level of the -systemic and -micro circulation and might offer benefit when compared to continues flow devices such as Impella. In contrast, IABP (which also offers pulsatile support), lacks the possibility of active unloading. Therefore, the combination of those features in the PulseCath iVAC2L is unique.
Combined endpoint: - All-cause death - Cardiogenic shock (SCAI stage C-E) - (Need for) renal replacement therapy - (Need for) mechanical ventilation - Ventricular arrhythmias leading to loss of cardiac output requiring CPR
Time frame: 30 days
PCWP (Δ max)
Time frame: Periprocedural
LVEDP (Δ max)
Time frame: Periprocedural
CO / CI / CPO (Δ max)
Time frame: Periprocedural
SvO2 (Δ max)
Time frame: Periprocedural
Drop in arterial pressure (MAP <60 OR SBP <90) for >10 minutes
Time frame: Periprocedural
Protected procedural success of Pulsecath iVAC2L
Proper placement and circulatory support of the device. Moreover, the device should be successfully weaned on the cardiac catheterization laboratory and maximally within 1 hour post CHIP procedure.
Time frame: Periprocedural
Procedural success of Pulsecath iVAC2L
Proper placement and circulatory support of the device. Moreover, the device should be successfully weaned \<6h post-procedural.
Time frame: <6 hours post-PCI
Rescue pVAD implantation
Time frame: From index PCI through hospital discharge (up to 30 days)
Highest Vasoactive Inotropic Score
Time frame: From index PCI through hospital discharge (up to 30 days)
Length of hospital stay
Time frame: From index PCI through hospital discharge (up to 30 days)
Cardiovascular death
Time frame: 30 days
Major adverse cardiovascular cerebral events (MACCE)
Time frame: 30-days
Stroke
Time frame: 30-days
PCI related myocardial infarction
Time frame: 48 hours
Myocardial infarction >48 hours post-PCI
Time frame: 30-days
Re-hospitalization or urgent hospital visit for heart failure
Time frame: 30 days
Major vascular events
Safety endpoint
Time frame: 30 days
Limb ischemia
Safety endpoint
Time frame: 30 days
Bleeding events (BARC 3 and 5)
Safety endpoint
Time frame: 30 days
Aortic valve injury
Safety endpoint
Time frame: 30 days
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — The publication rights in regard to the main results of the trial, i.e., regarding the primary and secondary objectives, belong to the sponsor. No individual investigator may publish on the results of this trial, or their own patients, without prior approval from the sponsor.
Supporting information: Study protocol
Started Jan 2024 (actual). Primary completion is estimated for Mar 2027, 37 months after the start.
Of 756 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 37 months is above that.
Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Amsterdam UMC, location VUmc →